景峯醫藥(000908.SZ):參股公司擬新一輪融資1000萬元
格隆匯11月27日丨景峯醫藥(000908.SZ)公佈,近日,公司接到持股32.44%的參股公司江蘇璟澤生物醫藥有限公司(“江蘇璟澤”)的通知,江蘇璟澤正引入投資方並進行內部重組。
江蘇璟澤致力於應用生物前沿技術進行創新生物藥物研究開發及產業化,技術涉及單/雙特異性抗體、重組蛋白、基因治療等領域。為滿足發展需求,江蘇璟澤決定引入新的投資方進行融資。具體如下:
該輪融資由杭州金智投資合夥企業(有限合夥)投資,投資額預計為1000萬元,原股東放棄優先認購權。投資款將全部用於生產經營和新業務發展。
此次江蘇璟澤融資事項為公司自願信息披露事項,不構成關聯交易,也不構成《上市公司重大資產重組管理辦法》規定的重大資產重組,無需提交董事會和股東大會審議。
江蘇璟澤的上述融資重組事項將不會對公司2019年經營狀況構成重要影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.